Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol
Open accessThe DOI matches its Crossref record; 100 of the 103 references it cites were found in a registry or an index; 43 of the 90 sources its claims cite were checked for support.
Abstract
Background: Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased attention over the past decades. Evidence-based approaches to prevent PGD are currently scarce, and not always effective. This paper introduces a protocol for a clinical trial exploring the effectiveness of a Meaning Reconstruction psychotherapy approach (MR) assisted with ayahuasca, a traditional indigenous medicine. Method: The outlined protocol is a three-arm, non-randomized controlled trial focused on reducing normal and pathological grief symptoms, comparing the effectiveness of Ayahuasca-assisted MR therapy (A-MR), MR therapy alone (MR) and No Treatment (NT). At least 69 people who lost a first-degree relative during the prior year, and with a Texas Revised Inventory of Grief score up 39 (TRIG ≥ 40), will participate in the trial. Participants will be allocated to an A-MR (n ≥ 23), MR (n ≥ 23) or NT (n ≥ 23) group. Those from the A-MR and MR therapy groups will undergo a therapeutic process involving 9 sessions of online psychotherapy. In addition, the A-MR condition involves 2 group sessions of ayahuasca. The primary outcomes will be normal and pathological grief severity as measured by the TRIG and Traumatic Grief Inventory Self-Report (TGI-SR), administered at baseline, post-treatment, and 3-month follow up. Measures of quality of life, post-traumatic growth, meaning-made, psychological flexibility, and self-belief consistency will be also included. In addition, subjective effects of ayahuasca and acceptance-avoidance promoting effects will be assessed following ayahuasca administration. Finally, we will analyze the potential mediating effect of meaning-made, psychological flexibility and self-belief consistency in grief symptoms (as measured by the TRIG and TGI). Discussion: This trial is the first to empirically examinate the potential of psychedelic-assisted psychotherapy for grief, as well as the potential processes of change that may account for it. Clinical trial registration: https://clinicaltrials.gov, identifier NCT06150859. Copyright © 2025 Sabucedo, Andión, Neimeyer, Soto-Angona, Javkin, Haro, Farré and González.
Overview
CoChat Summary
## TL;DR
This paper is a non-randomized clinical trial protocol testing whether ayahuasca-assisted Meaning Reconstruction therapy (A-MR) reduces grief symptoms better than Meaning Reconstruction therapy alone (MR) or no treatment (NT) in bereaved adults. It also plans to examine whether changes in meaning-made, psychological flexibility, and self-belief consistency mediate any effects.
## Key findings
- Not stated in the paper.
- The protocol plans a three-arm, non-randomized controlled trial with at least 69 participants and 84 to be recruited to allow for 20% dropout.
- Participants will be allocated to A-MR (n ≥ 23), MR (n ≥ 23), or NT (n ≥ 23).
- The primary outcomes are grief severity measured by TRIG and TGI-SR, assessed at baseline, post-treatment, and 3-month follow-up; secondary outcomes include quality of life and post-traumatic growth.
## Methods
- Design: Three-arm, non-randomized controlled trial protocol comparing A-MR, MR, and NT; participants are sequentially allocated.
- Sample/data: English- and Spanish-speaking adults aged 18–65 who lost a first-degree relative within the past 12 months and have TRIG ≥ 40; exclusions include psychosis history, hypertension, substance use disorder (except nicotine), and concurrent grief treatment.
- Analysis: Descriptive statistics, baseline group comparisons, repeated-measures ANOVA and/or linear mixed models, with Bonferroni corrections; mediation analyses for meaning-made, psychological flexibility, and self-belief consistency using lavaan.
## Limitations
- The paper states that sequential allocation may bias outcomes.
- It states that self-referral recruitment via psychedelic research/education institutions may limit generalizability to the general population.
- It states that using a plant concoction makes it difficult to determine which alkaloids and active compounds drive outcomes.
- Evident from the text: this is a protocol, so it reports planned analyses and hypothesized outcomes rather than trial results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 Valid · 1 Not valid · 17 Not checked · 5 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, elevated peripheral Brain-Derived Neurotropic Factor (BDNF) levels have been observed in healthy volunteers and clinically depressed patients two days following the ayahuasca administration, correlating with clinical improvement in those who were diagnosed with major depression (40).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Supportedcites [40] de Almeida, 2019, Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial, Front Psychol source
The Abstract and Discussion report higher serum BDNF 48 hours after ayahuasca than after placebo in both healthy controls and patients with treatment-resistant depression. The Discussion also reports that, among patients given ayahuasca, higher BDNF at that time was significantly correlated with fewer depressive symptoms. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Looking beyond the neurobiological evidence, several studies indicate that the therapeutic effect is experience-dependent (50, 51).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Not checked — no full text of the sourcecites [50] Brouwer, 2021, Pivotal mental states, J Psychopharmacology doi:10.1177/026988112095963
- Supportedcites [51] Ko, 2022, Psychedelics, mystical experience, and therapeutic efficacy: A systematic review, Front Psychiatry source
The Discussion reports an association between mystical experience and therapeutic outcome in most of the 12 studies reviewed, including significant correlations in nine studies and evidence of mediation in several. It concludes that the presence and intensity of the experience contribute to therapeutic efficacy, supporting the citing sentence's hedged claim. (LLM, conf=0.89)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A window for neuroplastic changes would appear to open a few hours after administration, lasting from a few days to a month (44).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Partly supportedcites [44] Calder, 2023, Towards an understanding of psychedelic-induced neuroplasticity, Neuropsychopharmacology sourceExperimental — accuracy not yet measured
The Conclusions say the neuroplasticity window appears to open within a few hours and may last a few days; changes formed during it may survive for at least a month. The duration section reports elevated BDNF two days after ayahuasca, but does not establish that ayahuasca specifically opens a window lasting up to a month. The claim conflates the window’s duration with the persistence of changes formed during it. (LLM, conf=0.89)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recent studies have shown that psychedelics reopen a critical period to induce metaplasticity, which dynamically regulates the potential for synaptic plasticity (46, 47).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Supportedcites [46] Nardou, 2023, Psychedelics reopen the social reward learning critical period, Nature source
The Abstract reports that psychedelics reopen the social reward learning critical period in mice, alongside metaplastic restoration of oxytocin-mediated plasticity. The “Metaplasticity, not hyperplasticity” section defines metaplasticity as dynamic regulation of the extent to which synaptic plasticity can be induced and reports evidence that psychedelics induce it. Page numbers are not provided in the supplied passages. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [47] Nardou, 2019, Oxytocin-dependent reopening of a social reward learning critical period with MDMA, Nature source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“in vitro, animal and human studies have demonstrated how harmine, tetrahydroharmine, harmaline (all three present in B. caapi) and dimethyltryptamine (present in P. viridis) stimulate adult neurogenesis and neuroplasticity, similarly to other serotoninergic psychedelic substances (40–43).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Partly supportedcites [40] de Almeida, 2019, Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial, Front Psychol sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that in vitro studies suggest neuronal proliferation, migration and differentiation from ayahuasca β-carbolines, and that harmine may increase hippocampal BDNF in rodents. It discusses neuroplasticity findings for 5-methoxy-N,N-dimethyltryptamine, which is distinct from the N,N-dimethyltryptamine named in the claim. The paper does not establish that each of the four named compounds stimulates adult neurogenesis and neuroplasticity in humans; its human trial measured serum BDNF instead. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [41] Kelley, 2022, Pharmahuasca and DMT rescue ROS production and differentially expressed genes observed after predator and psychosocial stress: Relevance to human PTSD, ACS Chem Neurosci source
- Partly supportedcites [42] Morales-García, 2017, The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro, Sci Rep sourceExperimental — accuracy not yet measured
The Discussion reports that harmine, tetrahydroharmine and harmaline stimulated adult neurogenesis in an in vitro model using cells from adult mice. It also says DMT was not tested and that in vivo neurogenesis remains for future study. The source therefore does not demonstrate the claimed effects for DMT, in animals or humans, or a comparable effect to other serotonergic psychedelics. (LLM, conf=0.90)
- Partly supportedcites [43] Morales-García, 2020, N, N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo, Trans Psychiatry sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that DMT promotes adult neurogenesis in vitro and in vivo and that earlier in vitro work found neurogenic effects of β-carbolines from B. caapi. It does not report human studies demonstrating that these compounds stimulate neurogenesis or neuroplasticity; the human studies it mentions concern ayahuasca’s antidepressant activity. It also identifies sigma-1 receptor activation, rather than a demonstrated similarity to other serotonergic psychedelics, as the mechanism of DMT’s neurogenic effect. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
13 more claims · 5 with their cited sources checked
Create a free account to see all 51 claims and to verify the 2 references still open.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 17
Citations
Cites
lavaan : An R Package for Structural Equation Modeling
Rosseel, Y. (2012) · Journal of Statistical Software · doi:10.18637/jss.v048.i02 · Cited by 27,955
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138 · cited 1×
“The following R packages will be used for data exploration, description, and preprocessing if necessary: tidyverse (80), car (81), moments version 0.14.1 (82), and nortest version 1.0-4 (83).”
InfluentialDevelopment of the World Health Organization WHOQOL-BREF Quality of Life Assessment
THE WHOQOL GROUP (1998) · Psychological Medicine · doi:10.1017/s0033291798006667 · Cited by 7,933 · cited 1×
“This questionnaire is a shorter version of the original WHOQOL-100 (67).”
TARGET ARTICLE: "Posttraumatic Growth: Conceptual Foundations and Empirical Evidence"
Tedeschi, R. G., & Calhoun, L. G. (2004) · Psychological Inquiry · doi:10.1207/s15327965pli1501_01 · Cited by 7,154 · cited 1×
“This questionnaire measures the degree of positive change experienced in the aftermath of a traumatic event (63, 64).”
Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018486.91360.00 · Cited by 4,686
International Statistical Classification of Diseases and Related Health Problems
(2011) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-0-387-79948-3_3055 · Cited by 4,151
Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., Waltz, T., & Zettle, R. D. (2011) · Behavior Therapy · doi:10.1016/j.beth.2011.03.007 · Cited by 3,950
THE DUAL PROCESS MODEL OF COPING WITH BEREAVEMENT: RATIONALE AND DESCRIPTION
Schut, M. S. (1999) · Death Studies · doi:10.1080/074811899201046 · Cited by 2,560
Self-concept clarity: Measurement, personality correlates and cultural boundaries
Campbell, J. D., Trapnell, P. D., Heine, S. J., Katz, I. M., Lavallee, L. F., & Lehman, D. R. (1996) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.70.1.141 · Cited by 2,088 · cited 1×
“This 12-item scale measure the clarity and cohesiveness of the person ’ s self-concept (76).”
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · cited 1×
“This design is based on the contemporary structure of PAP, which typically involves a three-stage framework encompassing preparation, facilitation, and integration (104).”
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Report of the Lancet Commission on the Value of Death: Bringing death back into life
Sallnow, L., Smith, R., Ahmedzai, S. H., Bhadelia, A., Chamberlain, C., Cong, Y., Doble, B., Dullie, L., Durie, R., Finkelstein, E. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02314-x · Cited by 807 · cited 2×
“On the other hand, people in Western countries are rapidly losing the cultural knowledge, tradition, and rites to cope with the death of a loved one (13).”
A short form of the Posttraumatic Growth Inventory
Cann, A., Calhoun, L. G., Tedeschi, R. G., Taku, K., Vishnevsky, T., Triplett, K. N., & Danhauer, S. C. (2010) · Anxiety, Stress, & Coping · doi:10.1080/10615800903094273 · Cited by 789 · cited 1×
“The internal consistency coef fi cient of the questionnaire is.86 -.89 (66).”
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 2×
“In this study, the 42-item version will be used (78), comprised of fi ve different dimensions: (1) Oceanic Boundlessness, (2) Anxious Ego, (3) Visionary Restructuralization, (4) Auditory Alterations, and (5) Reduction of Vigilance (RV).”
Gillies, J., & Neimeyer, R. A. (2006) · Journal of Constructivist Psychology · doi:10.1080/10720530500311182 · Cited by 678
Self-citationOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial
Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02565-4 · Cited by 455
Prevention of Mental Disorders: Effective interventions and policy options
Hosman, C. M. H., Jané‐Llopis, E., & Saxena, S. (2004) · Radboud Repository (Radboud University) · Cited by 421
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
The prevention and treatment of complicated grief: a meta-analysis
Wittouck, C., Van Autreve, S., De Jaegere, E., Portzky, G., & van Heeringen, K. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.09.005 · Cited by 361 · cited 1×
“Moreover, meta-analyses have shown that preventive therapies for PGD are not currently effective (16, 17).”
Tracking the reach of COVID-19 kin loss with a bereavement multiplier applied to the United States
Verdery, A. M., Smith-Greenaway, E., Margolis, R., & Daw, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007476117 · Cited by 360
Psychedelics reopen the social reward learning critical period
Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06204-3 · Cited by 358 · cited 2×
“This critical period is context-dependent and has been linked to the ability to induce social reward learning, psychological fl exibility, cognitive reappraisal and new patterns of behavior (46, 48, 49).”
Oxytocin-dependent reopening of a social reward learning critical period with MDMA
Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019) · Nature · doi:10.1038/s41586-019-1075-9 · Cited by 334 · cited 1×
“Recent studies have shown that psychedelics reopen a critical period to induce metaplasticity, which dynamically regulates the potential for synaptic plasticity (46, 47).”
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
Grief therapy and the reconstruction of meaning: From principles to practice
Neimeyer, R. A., Burke, L. A., Mackay, M. M., & van Dyke Stringer, J. G. (2010) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-009-9135-3 · Cited by 310
Self-citationPsychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
Tyndall, I., Waldeck, D., Pancani, L., Whelan, R., Roche, B., & Dawson, D. L. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2018.09.005 · Cited by 303
Biopsychosocial aspects of bereavement
Zisook, S. (1987) · American Psychiatric Press eBooks · Cited by 262
Meaning reconstruction in bereavement: Development of a research program
Neimeyer, R. A. (2019) · Death Studies · doi:10.1080/07481187.2018.1456620 · Cited by 242 · cited 6×
“The 9-session A-MR and MR can be subdivided into the three domains de fi ned in meaning reconstruction theory: the “ event story ” of the loss, the “ back story ” of the relationship with the deceased, and the “ personal story ” of self (37, 38) (Table 2): 1.”
InfluentialSelf-citationHartogsohn, I. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00129 · Cited by 229 · cited 1×
“The ayahuasca experience, therefore, could bring new information to the foreground to enrich the therapeutic process, providing an opportunity to transform maladaptive narratives about oneself, other people (including the deceased) or the world (56, 57).”
Johannsen, M., Damholdt, M. F., Zachariae, R., Lundorff, M., Farver-Vestergaard, I., & O'Connor, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.065 · Cited by 214
Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx036 · Cited by 200
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175
Yu, X.-N., Lau, J. T. F., Zhang, J., Mak, W. W. S., Choi, K. C., Lui, W. W. S., Zhang, J., & Chan, E. Y. Y. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.09.019 · Cited by 171 · cited 1×
“Total scores ≥ 32 indicate probable personal growth (65).”
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168
Continuing Bonds in Bereavement: New Directions for Research and Practice
(2017) · Routledge eBooks · doi:10.4324/9781315202396 · Cited by 162
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
Brouwer, A., & Carhart-Harris, R. L. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959637 · Cited by 143
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141
Montoya, A., Valladares, A., Lizán, L., San, L., Escobar, R., & Paz, S. (2011) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-9-18 · Cited by 140
Morales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., & Perez-Castillo, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01011-0 · Cited by 138
Rynearson, E. (2013) · Routledge eBooks · doi:10.4324/9780203769065 · Cited by 134
Prolonged grief disorder in ICD-11 and DSM -5-TR: Challenges and controversies
Eisma, M. C. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231154206 · Cited by 130 · cited 2×
“…culties of distinguishing normal from prolonged grief, and the arbitrariness involved in categorizing continuous variables such as distress or time (10), it has been argued that the requirement for these diagnoses may lead to people experiencing acute grief not receiving appropriate healthcare…”
Time does not heal all wounds: Mortality following the death of a parent
Rostila, M., & Saarela, J. M. (2011) · Journal of Marriage and Family · doi:10.1111/j.1741-3737.2010.00801.x · Cited by 125
Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
Bouso, J. C., Andión, Ó., Sarris, J. J., Scheidegger, M., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000438 · Cited by 118
Self-citationBoelen, P. A., Djelantik, A. A. A. M. J., de Keijser, J., Lenferink, L. I. M., & Smid, G. E. (2019) · Death Studies · doi:10.1080/07481187.2018.1480546 · Cited by 112
Complicated grief and the quest for meaning: A constructivist contribution
Neimeyer, R. A. (2006) · OMEGA - Journal of Death and Dying · doi:10.2190/eql1-ln3v-knyr-18tf · Cited by 109 · cited 1×
“…self-referred groups experiencing loss and transition (91) and mourners meeting criterial for PGD (92) have strongly supported the effectiveness of the model and, added to a growing literature, indicate that meaning-making prospectively predicts positive adaptation to bereavement (88, 92 – 95).”
Self-citationMeasuring meaning: Searching for and making sense of spousal loss in late life
Coleman, R. A., & Neimeyer, R. A. (2010) · Death Studies · doi:10.1080/07481181003761625 · Cited by 106
Self-citationRostila, M., Saarela, J., & Kawachi, I. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws163 · Cited by 94
An open trial of meaning-centered grief therapy: rationale and preliminary evaluation
Lichtenthal, W. G., Catarozoli, C., Masterson, M., Slivjak, E., Schofield, E., Roberts, K. E., Neimeyer, R. A., Wiener, L., Prigerson, H. G., Kissane, D. W., et al. (2019) · Palliative and Supportive Care · doi:10.1017/s1478951518000925 · Cited by 88
Self-citationPsychedelics therapeutics: What we know, what we think, and what we need to research
Nutt, D., Spriggs, M., & Erritzoe, D. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109257 · Cited by 84 · cited 1×
“PAP is demonstrating promising outcomes in treating a wide range of mental health issues, ranging from depression to post-traumatic stress disorder, suggesting this ef fi cacy may be transdiagnostic (20, 21).”
Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76
Therapeutic potential of ayahuasca in grief: a prospective, observational study
González, D., Cantillo, J., Pérez, I., Farré, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05446-2 · Cited by 75
Self-citationSuicidal ideation in bereavement: A systematic review
Molina, N., Viola, M., Rogers, M., Ouyang, D., Gang, J., Derry, H., & Prigerson, H. G. (2019) · Behavioral Sciences · doi:10.3390/bs9050053 · Cited by 74
Validation of the Integration of Stressful Life Experiences Scale–Short Form in a Bereaved Sample
Holland, J. M., Currier, J. M., & Neimeyer, R. A. (2014) · Death Studies · doi:10.1080/07481187.2013.829369 · Cited by 73
Self-citationPositive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Ennis, J., & Majid, U. (2021) · Death Studies · doi:10.1080/07481187.2019.1661884 · Cited by 68 · cited 1×
“The loss of a fi rst-degree family member signi fi cantly increases the risk of mortality, disease, and suicide for the mourner (2 – 6).”
Djelantik, A. A. A. M. J., Robinaugh, D. J., & Boelen, P. A. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114472 · Cited by 68
Prolonged grief and the disruption of meaning: Establishing a mediation model
Milman, E., Neimeyer, R. A., Fitzpatrick, M., MacKinnon, C. J., Muis, K. R., & Cohen, S. R. (2019) · Journal of Counseling Psychology · doi:10.1037/cou0000370 · Cited by 67
Self-citationRegret, Resilience, and the Nature of Grief
Cholbi, M. J. (2019) · Journal of Moral Philosophy · doi:10.1163/17455243-20180015 · Cited by 65 · cited 2×
“Although grief is a natural process, and serves a key existential purpose (7), this psychological process can go awry.”
Sloshower, J., Zeifman, R. J., Guss, J., Krause, R., Safi-Aghdam, H., Pathania, S., Pittman, B., & D’Souza, D. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-58318-x · Cited by 65
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
Elsey, J. W. B. (2017) · Drug Science Policy and Law · doi:10.1177/2050324517723232 · Cited by 57
Prolonged grief symptomatology following violent loss: The mediating role of meaning
Milman, E., Neimeyer, R. A., Fitzpatrick, M., MacKinnon, C. J., Muis, K. R., & Cohen, S. R. (2017) · European Journal of Psychotraumatology · doi:10.1080/20008198.2018.1503522 · Cited by 56
Self-citationLuoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Self-citationEvens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56 · cited 1×
“This period has been related to improvement in grief, depressive mood, stress, mindfulness, acceptance, emotion regulation, social behavior, wellbeing, and quality of life (45).”
Agin-Liebes, G., Zeifman, R., Luoma, J. B., Garland, E. L., Campbell, W. K., & Weiss, B. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221080165 · Cited by 54
Psychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Randomised controlled trial of a cognitive narrative intervention for complicated grief in widowhood
Barbosa, V., Sá, M., & Carlos Rocha, J. (2014) · Aging & Mental Health · doi:10.1080/13607863.2013.833164 · Cited by 47
Mortality in parents after the death of a child
Song, J., Mailick, M. R., Greenberg, J. S., & Floyd, F. J. (2019) · Social Science & Medicine · doi:10.1016/j.socscimed.2019.112522 · Cited by 46
Potential use of ayahuasca in grief therapy
González, D., Carvalho, M., Cantillo, J., Aixalá, M., & Farré, M. (2019) · OMEGA - Journal of Death and Dying · doi:10.1177/0030222817710879 · Cited by 44 · cited 1×
“Previous observational research, however, has suggested that the ceremonial use of ayahuasca has therapeutic value in reducing the severity of grief (34 – 36).”
Self-citationGarrido‐Hernansaiz, H., Rodríguez‐Rey, R., Collazo‐Castiñeira, P., & Collado, S. (2022) · Current Psychology · doi:10.1007/s12144-021-02645-z · Cited by 44 · cited 1×
“This questionnaire measures the degree of positive change experienced in the aftermath of a traumatic event (63, 64).”
Kelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
The Shipibo ceremonial use of ayahuasca to promote well-being: An observational study
Gonzalez, D., Cantillo, J., Perez, I., Carvalho, M., Aronovich, A., Farre, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623923 · Cited by 40 · cited 1×
“Several studies have evidenced that individuals who regularly use ayahuasca in a communal setting exhibit a higher level of general well-being, increased physical activity, and balanced diet than the general population (27 – 29).”
Stability Evaluation of DMT and Harmala Alkaloids in Ayahuasca Tea Samples
Silveira, G. D. O., SANTOS, R. G. D., Lourenço, F. R., Rossi, G. N., Hallak, J. E. C., & Yonamine, M. (2020) · Molecules · doi:10.3390/molecules25092072 · Cited by 38
Assessing a Buddhist treatment for bereavement and loss: The Mustard Seed Project
Neimeyer, R. A., & Young-Eisendrath, P. (2015) · Death Studies · doi:10.1080/07481187.2014.937973 · Cited by 36
Gómez-Sousa, M. D. L., Jiménez-Garrido, D. F., Oña, G., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001343 · Cited by 31
Burke, L. A., Neimeyer, R. A., Bottomley, J. S., & Smigelsky, M. A. (2019) · Illness, Crisis & Loss · doi:10.1177/1054137317699580 · Cited by 29
Self-citationAyahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review
White, E., Kennedy, T., Ruffell, S., Perkins, D., & Sarris, J. J. (2024) · International Journal of Toxicology · doi:10.1177/10915818241230916 · Cited by 27
Kohek, M., Ona, G., van Elk, M., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2077155 · Cited by 24
Reliability generalization of the Texas revised inventory of grief (TRIG)
Montano, S. A., Lewey, J. H., O’Toole, S. K., & Graves, D. (2016) · Death Studies · doi:10.1080/07481187.2015.1129370 · Cited by 23
González, D., Aixalà, M., Neimeyer, R. A., Cantillo, J., Nicolson, D., & Farré, M. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.832879 · Cited by 19 · cited 1×
“A detailed outline of this method of psychedelic integration has been published elsewhere, in the form of a case study (106).”
Self-citationRetelling the narrative of the death
(2012) · Techniques of Grief Therapy · doi:10.4324/9780203152683-32 · Cited by 16 · cited 1×
“The fi rst phase is focused on the employment of non-directive narrative retelling to help the participant revisit the story of the loss, and the stressful or traumatic memories connected to it (37, 96, 97).”
Self-citationAttachment security and continuing bonds: The mediating role of meaning-made in bereavement
Tidwell, B. L., Larson, E. D., & Bentley, J. A. (2021) · Journal of Loss and Trauma · doi:10.1080/15325024.2020.1753389 · Cited by 15
From retelling to reintegration: Narrative fixation and the reconstruction of meaning
Neimeyer, R. A., & Rynearson, E. (. (2022) · The Restorative Nature of Ongoing Connections with the Deceased · doi:10.4324/9781003105077-12 · Cited by 15
Self-citationThe meaning in loss protocol: A clinical trial of online grief therapy
Batista, J., Alves, D., Pires, N., Silva, J. R., Mendes, I., Magalhães, C., Rosa, C., Oliveira, J. T., Gonçalves, M. M., & Neimeyer, R. A. (2025) · Death Studies · doi:10.1080/07481187.2024.2370633 · Cited by 12
Self-citationShevlin, M., Redican, E., Murphy, J., Hyland, P., & Karatzias, T. (2023) · Journal of Traumatic Stress · doi:10.1002/jts.22972 · Cited by 11
Meaning-making in bereavement transitions: Review and clinical relevance
Milman, E., & Neimeyer, R. A. (2020) · Navigating Life Transitions for Meaning · doi:10.1016/b978-0-12-818849-1.00005-9 · Cited by 7 · cited 2×
“This measure involves a self-assessment of “ meaning made ” , as the successful outcome of meaning-making after stressful life experiences (69, 70).”
Self-citationLee, S. A., Neimeyer, R. A., Ng, C., Veglahn, L., & Tucci, A. S. (2024) · Death Studies · doi:10.1080/07481187.2024.2364495 · Cited by 6 · cited 1×
“Scores above 14 on the ISLES-SF have been found to re fl ect clinically signi fi cant functional impairment in family, occupational and social contexts (71).”
Self-citationProneness to painful self-conscious emotions, meaning, and PTSD in veterans
Slagel, B. A., Taylor, S. E., Borgonga, N. C., & Currier, J. M. (2020) · Journal of Loss and Trauma · doi:10.1080/15325024.2019.1682343 · Cited by 5
The therapeutic use of ayahuasca in grief
González, D., Aronovich, A. A., & Carvalho, M. (2021) · Ayahuasca Healing and Science · doi:10.1007/978-3-030-55688-4_12 · Cited by 5
Self-citationLee, S. A., Caycho‐Rodríguez, T., Vilca, L. W., & Neimeyer, R. A. (2024) · Death Studies · doi:10.1080/07481187.2024.2368330 · Cited by 5
Self-citationChow, A. Y. M., & Chu, K. S. M. (2015) · Techniques of Grief Therapy · doi:10.4324/9781315692401-58
Research works printed but not linked: 10
- 2022, Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR
- Neimeyer, 2023, “Grief Therapy as a Quest for Meaning”. In: Steffen EM, Milman E, Neimeyer RA, editors, The Handbook of Grief Therapies.
- McKenna, 1999, Ayahuasca: An ethnopharmacologic history, 187
- Faschingbauer, 1981, The Texas Revised Inventory of Grief manual
- Faschingbauer, 1987, The Texas revised inventory of grief
- Dittrich, 2010, 5D-ASC: Questionnaire for the assessment of altered states of consciousness: A short introduction
- 2023, R: A Language and Environment for Statistical Computing
- Fox, 2019, An R companion to applied regression
- Hedtke, 2016, Introducing the deceased
- Lundgren, 2018, Values choice and clarification
Cited by
Grief as a Quest for Meaning: Review of a Research Program
Neimeyer, R. A. (2026) · Journal of Constructivist Psychology · doi:10.1080/10720537.2026.2688401 · Cited by 7
Self-citationSoto-Angona, Ó., Andión, Ó., Sabucedo, P., Neimeyer, R. A., Haro, J. M., Javkin, J., Farré, M., & González, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-13251-5 · Cited by 5
Self-citationRegistered Clinical Trials of Ayahuasca and DMT : A Scoping Review
Stojanovic, T., Nilsson, K. W., Fredriksson, R., Schiöth, H. B., & Moulin, T. C. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70311 · Cited by 3
Psychedelic-assisted grief therapy: a mixed-method case study
Sabucedo, P., Evans, C., Nicolson, D., Farré, M., & González, D. (2024) · Mortality · doi:10.1080/13576275.2024.2434456 · Cited by 2
“The 9-session MRT protocol (see Sabucedo et al., 2024) can be subdivided into three distinct treatment phases, each focused on a different mechanism of change according to the model.”
Self-citationTorales, J. C., O’Higgins, M., Barrios, I., Caycho-Rodríguez, T., Castaldelli-Maia, J. M., & Ventriglio, A. (2026) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_489_25
Metadata
- Authors
- Sabucedo, P., Andión, O., Neimeyer, R. A., Soto-Angona, O., Javkin, J., Haro, J. M., Farré, M., & González, D.
- Affiliations
- University of Liverpool (GB)
- Sociedad española de medicina psicodélica (ES)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Universidad Isabel I (ES)
- Corresponding author
- González, Débora
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2025-01-07
- Volume
- 15
- Pages
- 1484736-1484736
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC11747804
- OpenAlex
- W4406127324
- Cited by
- 6
- References
- 103
- Citations by year
- 2026: 4 · 2025: 1
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Update notices
- corrigendum (2025-04-01)
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Grief, Bereavement, and Mental Health
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- prolonged grief disorder, ayahuasca, psychedelic-assisted psychotherapy, grief, online therapy, psychological flexibility, posttraumatic growth, traumatic grief
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
